Castle Biosciences Valuation
Is CSTL undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CSTL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CSTL ($28.88) is trading below our estimate of fair value ($93.32)
Significantly Below Fair Value: CSTL is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CSTL?
Key metric: As CSTL is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is CSTL's PE Ratio? | |
|---|---|
| PE Ratio | 133.1x |
| Earnings | US$6.08m |
| Market Cap | US$796.81m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.7x |
| Enterprise Value/EBITDA | 43.8x |
| PEG Ratio | -3.1x |
Price to Earnings Ratio vs Peers
How does CSTL's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 27x | ||
DCGO DocGo | 13.6x | -50.7% | US$418.4m |
PNTG Pennant Group | 49.5x | 30.0% | US$1.1b |
SBC SBC Medical Group Holdings | 12.3x | n/a | US$639.1m |
VMD Viemed Healthcare | 32.5x | 32.5% | US$332.5m |
CSTL Castle Biosciences | 133.1x | -42.4% | US$796.8m |
Price-To-Earnings vs Peers: CSTL is expensive based on its Price-To-Earnings Ratio (133.1x) compared to the peer average (27x).
Price to Earnings Ratio vs Industry
How does CSTL's PE Ratio compare vs other companies in the US Healthcare Industry?
Price-To-Earnings vs Industry: CSTL is expensive based on its Price-To-Earnings Ratio (133.1x) compared to the US Healthcare industry average (25.8x).
Price to Earnings Ratio vs Fair Ratio
What is CSTL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 133.1x |
| Fair PE Ratio | 9.6x |
Price-To-Earnings vs Fair Ratio: CSTL is expensive based on its Price-To-Earnings Ratio (133.1x) compared to the estimated Fair Price-To-Earnings Ratio (9.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$28.88 | US$41.56 +43.9% | 9.8% | US$50.00 | US$36.00 | n/a | 9 |
| Nov ’25 | US$33.15 | US$37.33 +12.6% | 13.5% | US$45.00 | US$28.00 | n/a | 9 |
| Oct ’25 | US$28.09 | US$35.56 +26.6% | 12.2% | US$45.00 | US$28.00 | n/a | 9 |
| Sep ’25 | US$29.67 | US$35.56 +19.8% | 12.2% | US$45.00 | US$28.00 | n/a | 9 |
| Aug ’25 | US$23.04 | US$34.33 +49.0% | 9.6% | US$40.00 | US$28.00 | n/a | 9 |
| Jul ’25 | US$21.19 | US$34.33 +62.0% | 9.6% | US$40.00 | US$28.00 | n/a | 9 |
| Jun ’25 | US$23.26 | US$34.33 +47.6% | 9.6% | US$40.00 | US$28.00 | n/a | 9 |
| May ’25 | US$22.02 | US$33.11 +50.4% | 9.2% | US$37.00 | US$28.00 | n/a | 9 |
| Apr ’25 | US$22.25 | US$33.11 +48.8% | 9.2% | US$37.00 | US$28.00 | n/a | 9 |
| Mar ’25 | US$19.94 | US$32.63 +63.6% | 8.8% | US$37.00 | US$28.00 | n/a | 8 |
| Feb ’25 | US$23.68 | US$31.67 +33.7% | 12.5% | US$37.00 | US$25.00 | n/a | 9 |
| Jan ’25 | US$21.58 | US$31.56 +46.2% | 12.7% | US$37.00 | US$25.00 | n/a | 9 |
| Dec ’24 | US$19.97 | US$33.00 +65.2% | 12.9% | US$40.00 | US$25.00 | n/a | 8 |
| Nov ’24 | US$15.70 | US$33.00 +110.2% | 12.9% | US$40.00 | US$25.00 | US$33.15 | 8 |
| Oct ’24 | US$16.89 | US$33.00 +95.4% | 12.9% | US$40.00 | US$25.00 | US$28.09 | 8 |
| Sep ’24 | US$19.66 | US$33.00 +67.9% | 12.9% | US$40.00 | US$25.00 | US$29.67 | 8 |
| Aug ’24 | US$16.72 | US$33.63 +101.1% | 13.1% | US$40.00 | US$25.00 | US$23.04 | 8 |
| Jul ’24 | US$13.72 | US$33.63 +145.1% | 13.1% | US$40.00 | US$25.00 | US$21.19 | 8 |
| Jun ’24 | US$21.05 | US$44.50 +111.4% | 19.0% | US$60.00 | US$35.00 | US$23.26 | 8 |
| May ’24 | US$22.75 | US$44.63 +96.2% | 16.6% | US$60.00 | US$38.00 | US$22.02 | 8 |
| Apr ’24 | US$22.72 | US$45.88 +101.9% | 16.1% | US$60.00 | US$38.00 | US$22.25 | 8 |
| Mar ’24 | US$22.86 | US$46.38 +102.9% | 15.7% | US$60.00 | US$38.00 | US$19.94 | 8 |
| Feb ’24 | US$27.52 | US$49.63 +80.3% | 16.5% | US$63.00 | US$40.00 | US$23.68 | 8 |
| Jan ’24 | US$23.54 | US$48.86 +107.5% | 17.8% | US$63.00 | US$40.00 | US$21.58 | 7 |
| Dec ’23 | US$24.05 | US$48.86 +103.1% | 17.8% | US$63.00 | US$40.00 | US$19.97 | 7 |
| Nov ’23 | US$25.82 | US$49.86 +93.1% | 16.3% | US$63.00 | US$40.00 | US$15.70 | 7 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Lantheus Holdings
US$6.0b
Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.
LNTH
US$87.32
7D
8.0%
1Y
27.8%
Centene
US$29.8b
Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.
CNC
US$60.35
7D
2.8%
1Y
-18.7%
electroCore
US$64.1m
A commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.
ECOR
US$9.92
7D
-27.1%
1Y
80.4%